AB Science SA · EURONEXT:AB
AB Science SA — Corporate Update (November 2019)
46 slides from AB Science SA's corporate update, Nov 20, 2019
Slide 1: AB Science Webconference: Masitinib in Indolent Systemic Mastocytosis
AB SCIENCE WEBCONFERENCE MASITINIB IN INDOLENT SYSTEMIC MASTOCYTOSIS 20 November 2019
Slide 2: Disclaimer
Disclaimer This presentation, together with the material set forth herein, does not constitute an offer of securities for sale nor the solicitation of an offer to purchase securities in any jurisdiction. Distribution of such presentation in certain jurisdiction may constitute a breach of applicable
Slide 3: Agenda
AGENDA Introduction of participating experts Current results with masitinib in ISM Design of confirmatory study and pathway to registration Experts’ Opinions Q&A
Slide 4: Participating Experts in Mastocytosis
Presenting KOL Participating Experts in Mastocytosis Cem AKIN, MD, PhD Dr. Akin is currently a Professor of Allergy and Immunology in the Department of Internal Medicine at the University of Michigan. He is co-chair of the steering committee of the American Initiative in Mast Cell Diseases (AIM). Mi
Slide 5: Masitinib positioning
Masitinib positioning The planned indication for masitinib is indolent or smouldering systemic mastocytosis, which are the most prevalent forms of mastocytosis. Disease according to WHO % Masitinib Category Characteristics Symptoms classification patients scope Cutaneous mastocytosis (CM) Primarily
Slide 6: Indolent or Smouldering Systemic Mastocytosis
Indolent or Smouldering Systemic Mastocytosis Patient with Indolent SM experience multiple symptoms, which can be severe and considered for some patients as not tolerable. Cognitive impairment and depression are prominent features of the disease. Symptom Rank Controls Patients P-value Hermine et al.
Slide 7: Masitinib profile
Masitinib profile Masitinib is a selective kinase inhibitor that targets mast cells and macrophages/microglia. Kinase inhibition profile of masitinib Masitinib targets mast cells Cellular Target Molecular Target IC50 [nM] Kd [µM] Masitinib is a potent and selective inhibitor of mast cells o Wild-t
Slide 8: Masitinib profile: mechanism of action
Masitinib profile Masitinib inhibits mast cells, regardless of c-Kit mutation status, through inhibition of c-Kit, Lyn and Fyn kinases. Illustration of masitinib MoA in mastocytosis The c-Kit receptor is primarily responsible for mast cell growth, differentiation and survival with mast cell mediator
Slide 9: Masitinib safety database
Masitinib safety database The safety profile of masitinib is sufficiently understood with over 6,000 patients enrolled in clinical studies. Patient exposure as of February 2018* Safety population Patients exposed for at least (months) All >6 > 12 Healthy Volunteers subjects 114 0 0 Non Oncology subj
Slide 10: ISM – Clinical Development
ISM – Clinical Development The clinical program in mastocytosis is comprised of 2 proof of concept studies (one published), one phase 3 study (published), and one phase 3 confirmatory study. Primary Patient Study Related Phase Design Population endpoint target status publications Patients with masto
Slide 11: ISM – Proof of concept studies
ISM – Proof of concept studies Clinical proof of concept has been established both in patients with and without D816V c-Kit mutation. Phase 2 Phase 2 Phase 1 AK002 patients not bearing activating point patients bearing activating point mutations (N = 11 ISM patients)) mutations in the phosphotransfe
Slide 12: ISM – Proof of concept studies
ISM – Proof of concept studies The majority of patients in phase 2 chose to remain on masitinib over the long term, and some have been treated for up to 7 years. Duration of treatment exposure with masitinib in indolent systemic mastocytosis (Pooled phase 2; n=46 patients) Exposure to treatment Pati
Slide 13: ISM – Proof of concept studies
ISM – Proof of concept studies Masitinib also had an effect on mast cells in the skin, as shown by the reduction in urticaria pigmentosa. Cutaneous effects of masitinib treatment in a male patient before (2007) and after (2014) continuous masitinib therapy (Study AB06013). 2007 2014 13
Slide 14: ISM – Proof of concept studies
ISM – Proof of concept studies Preliminary evidence suggest that masitinib may be able to reverse cerebral hypoperfusion in mastocytosis patient, correlating with improved cognitive function. Representative images from mastocytosis patient comparing ASL-MRI before masitinib treatment (A) and after 6
Slide 15: ISM – Phase 3 study
ISM – Phase 3 study The first phase 3 study (AB06006) evaluated masitinib versus placebo in 135 patients with ISM and severe symptoms at baseline. Study Design : Blinded, placebo controlled, masitinib versus placebo, Randomization 1:1 Masitinib 6 mg/kg/day 135 patients with ISM To be eva
Slide 16: ISM – Phase 3 study
ISM – Phase 3 study Pre-specified primary and secondary analyses on symptoms were positive and supported efficacy based on odds ratio. AB06006 – Analyses based on symptoms (n=135 ISM patients with severe symptoms) Masitinib Placebo p-value Odds ratio 4H75% Primary Cumulative 75% response rate on bas
Slide 17: ISM – Phase 3 study
ISM – Phase 3 study Masitinib also demonstrated significant activity on objective markers of mast cell activation and burden. AB06006 – Analyses based on objective endpoints Masitinib Placebo p-value Tryptase - Patients with baseline tryptase ≥20 µg/L 46 44 0.0001 Average relative change from baseli
Slide 18: ISM – Phase 3 study
ISM – Phase 3 study The most frequent severe adverse events were related to gastrointestinal disorders and skin cutaneous disorders. No life-threatening toxicities occurred. AB06006 – All severe AEs during 24-week treatment period with at least one event in the masitinib treatment-arm Masitinib Plac
Slide 19: ISM – Phase 3 study
ISM – Phase 3 study Results from this phase 3 study were published in The Lancet in 2017. 19
Slide 20: ISM – Phase 3 confirmatory study design
ISM – Phase 3 confirmatory study design Three optimizations of the phase 3 confirmatory study have been implemented based on the first phase 3 and are increasing the probability of success of the study. DESIGN OPTIMIZATIONS FROM PREVIOUS PHASE 2/3 ❖ Double blind, placebo controlled, randomized 1:1 ❖
Slide 21: Phase 3 confirmatory study regulatory status
ISM – Phase 3 confirmatory study regulatory status The phase 3 confirmatory study is being initiated and patient enrolment is expected to be initiated in Q1 2020. Europe Design reviewed through 2 scientific advices plus input from registration dossier Protocol approved in France (ANSM) and oth
Slide 22: Phase 3 confirmatory study timelines
ISM – Phase 3 confirmatory study timelines The confirmatory study is expected to be completed early 2022. Start date: Q1 2020 Patient enrolment: 18 months Enrolment : 140 patients Identified sites : 30 sites, only hematology centers Average enrolment : around 5 patients per site over 18 mo
Slide 23: Masitinib Intellectual Property
Masitinib Intellectual Property Masitinib IP rights are secured up to 2031 in the US and potentially 2036 in Europe in ISM. Protection Item Duration of protection Status Masitinib has been granted orphan drug Exclusivity of 7 years for FDA Orphan drug status Delivered designation by both EMA and FDA
Slide 24: Mariana Castells, MD, PhD
Mariana CASTELLS, MD, PhD About Mariana Castells Professor at Harvard Medical School. She is a clinician/teacher/researcher at the Brigham and Women’s Hospital Rheumatology, Immunology and Allergy Division serving as Director of Drug Hypersensitivity and Rapid Desensitization Center and the Dire
Slide 25: Mariana Castells
Mariana Castells There is a high unmet medical need for patients with indolent forms of systemic mastocytosis. About the Brigham and Women’s Hospital (BWH) Mastocytosis Center in Boston The BWH Mastocytosis Center in Boston is pioneer in basic , translational and clinical research in mast cell d
Slide 26: Mariana Castells
Mariana Castells Masitinib has a benefit and toxicity profile which sets it apart from other current tyrosine kinase , with a more favorable benefit ratio and with great potential to improve the quality of life of ISM patients. Key differentiating factors with masitinib Safety profile o No appar
Slide 27: Cem Akin, MD, PhD
Cem AKIN, MD, PhD About Cem Akin Professor of Allergy and Immunology in the Department of Internal Medicine at the University of Michigan. Co-chair of the steering committee of the American Initiative in Mast Cell Diseases (AIM). Member of the Scientific Advisory Board of ECNM. Consultancy
Slide 28: Cem Akin
Cem Akin Masitinib is currently the only drug in phase 3 for a claim on indolent systemic mastocytosis. Main Forms of Drug Sponsor Target Status Differentiating point mastocytosis Midostaurin Novartis Multi-kinase Registered Aggressive Blueprint Not competing with masitinib Avapritinib Kit 816 Phase
Slide 29: Activation of mast cells leads to degranulation and secretion of mediators
Activation of mast cells leads to degranulation and secretion of numerous mediators that are thought to contribute to the multiple symptoms observed in patients. Clinically Relevant Mediators Released from Mast Cells and Putative Effects Theoharides T., Valent P., Akin C., NEJM 2015. Mast Cells, Mas
Slide 30: Imatinib suppresses mast cell production without adverse clinical event
KIT-targeting drug imatinib suppresses mast cell production in vitro and in vivo. However, drug- induced mast cell depletion is not accompanied by adverse clinical event. Imatinib induces mast cell deficiency in the bone marrow of patients with CML. Bone marrow (BM) biopsy material was obtained from
Slide 31: Masitinib demonstrated a positive benefit risk balance
Masitinib demonstrated a positive benefit risk balance in a large controlled study. Clinically relevant efficacy on key severe symptoms Efficacy on depression and asthenia Efficacy on flush and pruritus Response based on 75% reduction of severity of symptoms Favorable safety profile Most
Slide 32: Michel Arock, PharmD, PhD
Michel AROCK, PharmD, PhD About Michel Arock Professor of physiology and hematology at the Ecole Normale Supérieure of Paris-Saclay and is currently heading the Functional Unit for Biological Emergencies within the Hospital Pitié-Salpêtrière Charles-Foix in Paris. Conducted research on the phy
Slide 33: Michel Arock: need to reduce symptoms in ISM/SSM
Michel Arock For patients with ISM/SSM, the need is to reduce symptoms, which can be severe. Mastocytosis can be categorized into cutaneous mastocytosis (CM; mainly children, but some adults have also pure CM) and systemic mastocytosis (SM) and other internal organs, involving the bone marrow. S
Slide 34: Michel Arock: conventional symptomatic treatments
Michel Arock Patients with ISM/SSM receive multiple conventional symptomatic treatments, which are in most cases unable to reduce symptomatology. Treatment Symptoms Selective serotonin reuptake inhibitors (SSRIs) Depression H1 Antagonists Pruritus, flush and sometimes GI pains H2 Antagonists Essenti
Slide 35: Michel Arock: urgent need of new drugs
Michel Arock Therefore, there is an urgent need of new drugs able to significantly improve severe symptoms in ISM/SSM and devoid of significant adverse effects. Among the new drugs, the most promising are tyrosine kinase inhibitors (TKIs). However, Midostaurin and Avapritinib, two TKIs active in
Slide 36: Q&A
Q& A 36
Slide 37: Appendices
APPENDICES
Slide 38: Mastocytosis
Mastocytosis Mastocytosis is a set of diseases characterized by an abnormal accumulation of mast cells in one or more organ systems. The disease is primarily driven by the KIT D816V mutation. WHO Classification of mastocytosis (2016) Cutaneous mastocytosis (CM) ≈ 30% Systemic mastocytosis (SM) Sympt
Slide 39: Mastocytosis
Mastocytosis Patients with Indolent SM have a (nearly) normal life expectancy, while patients with aggressive mastocytosis have a median overall survival of approximately four years. Kaplan Meier Survival for systemic mastocytosis patients classified by type Indolent Mastocytosis Aggressive Mastocyt
Slide 40: Aggressive Mastocytosis
Aggressive Mastocytosis Aggressive mastocytosis can be stratified, based on MARS clinical and molecular criteria, in three risk-groups, each requiring different therapeutic options, and for which masitinib is not a candidate. Jawhar et al., Blood 2017. Jawhar et al., JCO 2019 40
Slide 41: Masitinib profile
Masitinib profile Masitinib inhibits mast cell hyper-activation in a manner that is independent of mutant-KIT (D816V) signaling pathways and which demonstrates cytostatic, disease-modifying properties. Masitinib potently inhibits degranulation in a model of mast cell hyperactivation. Reduction of ma
Slide 42: ISM – Phase 3 study
ISM – Phase 3 study Similar efficacy was reported in patients with D816V mutation. AB06006 – Analyses based on symptoms (n= 116 ISM patients with severe symptoms) Masitinib Placebo p-value Odds ratio 4H75% Cumulative 75% response rate on baseline symptoms 20.2% 7.4% 0.0316 4.45 among pruritus or flu
Slide 43: ISM – Phase 3 study
ISM – Phase 3 study Clinical relevance of the results is supported by patient response analysis. AB06006 – Analyses based on patient response Patient response rate 4H: Number of patients having response (≥75%) on at least 1 handicap Patient response on at least one Overall W8-W24 – Pearson Chi-Squ
Slide 44: ISM – Phase 3 study
ISM – Phase 3 study The pre-specified primary analysis based on 4H75% endpoint and the GEE model is most appropriate to demonstrate the clinical relevance of masitinib in the claimed indication. The composite endpoint selected, although complex, was the most appropriate for the disease Key paramet
Slide 45: ISM – Targeted population
ISM – Targeted population Adult population with indolent systemic mastocytosis is estimated to be around 65,000 in the USA and in the EU. Europe US Population (’000) 500 0001 320 0001 Mastocytosis with Symptoms (ISM-SY4) 1/10,0002 Adult population 78%3 Potential Patients, adults with ISM-SY 40,000 2
Slide 46: Commercialization
Commercialization AB Science is ideally positioned to commercialize masitinib in mastocytosis in case of registration. In severe systemic mastocytosis in adults No No registered drug Competition No drug in phase 3 clinical development Network of physician specialists already structured in Euro